Zheng Quan Zhi Xing·2025-07-18 09:17Group 1 - The fund is named "Innovative Drug ETF Hong Kong-Shanghai-Shenzhen" and is managed by Tibet Dongcai Fund Management Co., Ltd. [2] - The fund aims to closely track the performance of the underlying index, minimizing tracking deviation and error [2][10]. - As of the end of the reporting period on June 30, 2025, the total fund shares amounted to 236,603,238 [2][14]. Group 2 - The fund's investment strategy primarily employs a full replication method, constructing the investment portfolio based on the composition and weight of the underlying index [2][10]. - The fund's performance benchmark is the China Securities Index for the innovative drug industry, which reflects the overall performance of listed companies in this sector [4][10]. - The fund's net asset value growth rate for the reporting period was 8.60%, outperforming the benchmark return of 7.86% [10]. Group 3 - The fund's asset allocation as of the reporting period includes 97.67% in stocks, with no holdings in bonds or asset-backed securities [11]. - The healthcare sector represents 41.91% of the fund's net asset value, indicating a significant focus on this industry [12][13]. - The fund's total subscription during the reporting period was 80,000,000 shares, while total redemptions were 76,000,000 shares [14].